Filing Flows › Orchestra BioMed Holdings (OBIO) › Q4 2024
Orchestra BioMed Holdings (OBIO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Orchestra BioMed Holdings (OBIO) reported revenue of $253K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and -74% from the quarter before.
Orchestra BioMed Holdings, Q4 2024: revenue $253K (-3% year over year), net loss $16.2M, operating cash flow −$13.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $253K | -74% | -3% |
| Operating profit | −$16.7M | — | — |
| Net earnings | −$16.2M | — | — |
| Operating cash flow | −$13.5M | — | — |
What changed
Revenue was $253K in Q4 2024, down 3% year over year and down 74% from the previous quarter. Product revenue was the largest line at 70% of revenue.
Operating costs exceeded revenue by $16.7M, an operating margin of -6591.7%. Total costs grew 33% against a revenue fall of 3%. The fastest-growing cost line was SG&A (+41%). The quarter ended with a net loss of $16.2M, wider than the previous quarter's $15.4M loss.
Operating cash flow was −$13.5M. Non-cash charges added back $84K of depreciation and $2.9M of share-based compensation. Capital expenditures of $106K exceeded it, leaving free cash flow of −$13.6M.
Questions
What was Orchestra BioMed Holdings' revenue in the fourth quarter 2024?
Orchestra BioMed Holdings (OBIO) reported revenue of $253K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and -74% from the quarter before.